Other languages Veracyte, Inc.

Equities

VCYT

US92337F1075

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
20.13 ^USD	+2.86%		+1.16%	-26.83%

04-15	Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating	MT
02-26	Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Mixed Premarket Friday	02-23
Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024	02-22
Veracyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22
Veracyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22
Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors	02-13
Veracyte Closes $70 Million C2i Genomics Acquisition	02-06
Veracyte, Inc. completed the acquisition of C2i Genomics, Inc.	02-04
Veracyte, Inc. Provides Preliminary Unaudited Earnings Results for Fourth Quarter and Full Year Ended December 31, 2023	01-08
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday	12-04
Veracyte Says New Data Backs Utility of Decipher Genomic Classifier to Treat, Manage Prostate Cancer	12-01
Veracyte's Q3 Loss Widens, Revenue Increases; Raises 2023 Revenue Outlook	11-08
Veracyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07
Veracyte, Inc. Raises Revenue Guidance for the Full Year 2023	11-07
Veracyte Says New Phase 3 Trial Data Further Validates Decipher Prostate Genomic Classifier's Value	04/10/23
Veracyte, Inc. Announces New Data from A Large, Randomized Phase 3 Trial Reinforce the Value of the Decipher Prostate Genomic Classifier in Helping Physicians Make More Informed Treatment Decisions for Their Patients with Prostate Cancer	04/10/23
Veracyte, Inc. Announces New Data Presented At the 2023 American Thyroid Association Annual Meeting Demonstrate That Veracyte's Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer	28/09/23
Veracyte, Inc. Appoints Phillip G. Febbo as Chief Scientific Officer and Chief Medical Officer, Effective 2, 2023	27/09/23
Veracyte, Inc. and Gustave Roussy Announces Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies	06/09/23
Veracyte, Inc. Announces Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer	22/08/23
Veracyte Q2 Loss Narrows, Revenue Increases; Raises 2023 Revenue Guidance	09/08/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Veracyte, Inc.

Equities

VCYT

US92337F1075

Other languages

Filters